Form 4: Baker Bros. Advisors Report Acquisition of IGM Biosciences Stock Units

Baker Bros. Advisors LP reports the acquisition of restricted stock units in IGM Biosciences on behalf of several entities due to director compensation.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of IGM Biosciences, Inc. (IGMS) stock.
• The reported transaction involves the acquisition of 1,994 restricted stock units (RSUs) by Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, in lieu of director retainer fees of $11,500.
• These RSUs are fully vested and were issued under IGM Biosciences' Outside Director Compensation Policy.
• The filing also clarifies the indirect beneficial ownership of common stock held by various Baker Bros. entities, including 667, L.P. and Baker Brothers Life Sciences, L.P.
• Baker Bros. Advisors LP serves as the investment advisor to these funds but disclaims direct pecuniary interest in the securities, except to the extent of their pecuniary interest therein.
• Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the common stock, stock options, and RSUs due to their ownership interest in the general partners of the funds.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard business operations and director compensation practices. The sentiment is neutral to slightly positive due to the alignment of director interests with company performance.

Positives

• The acquisition of RSUs reflects ongoing director compensation, aligning director interests with the company's performance.
• The filing provides transparency regarding the ownership structure and indirect beneficial ownership of IGM Biosciences stock by Baker Bros. entities.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Director compensation in the form of stock and restricted stock units is a common practice among publicly traded biotechnology companies, such as Amgen, Regeneron, and Gilead Sciences, to align the interests of directors with those of shareholders.
• The structure of indirect ownership through investment advisors and limited partnerships is also a common arrangement in the investment management industry, similar to firms like BlackRock and Vanguard.

Stakeholder Impact

• Shareholders: Provides transparency regarding insider ownership and compensation.
• Directors: Details compensation structure and alignment with company goals.

Key Dates